At the 2026 Chery International User Summit, Chery introduced a connected mobility ecosystem featuring a Level 4 Robotaxi, two eVTOL aircraft models, and a Super Intelligent Valet Parking system. This integrated approach aims to reduce modal transfers and overcome geographic challenges by linking land and low-altitude air travel with smart parking and charging technologies. The system promises shorter wait times, simpler modal transitions, and greater travel control, marking Chery's shift from standalone vehicles to a coordinated transport network. This innovation could transform urban and intercity travel by enhancing efficiency and accessibility.
The story on Chery's integrated mobility ecosystem offers context from Pluang's Consumer Cyclical sector data as of Nov 15, 2026 19:11 WIB. Among 134 priced US stocks, 82 rose and 50 fell. Notably, PLBY gained 4.92% with 100% buy orders and a typical hold time of 25 days, contrasting with QS and NIO, which dropped 5.15% and 4.92% respectively, with longer hold times of 39 and 83 days.
At the 2026 Chery International User Summit, Chery introduced a new integrated travel ecosystem combining autonomous Robotaxi, electric vertical takeoff and landing (eVTOL) aircraft, and advanced smart valet parking. This system aims to connect land ...
At the 2026 Chery International User Summit, Chery introduced a connected mobility ecosystem combining a Level 4 Robotaxi, eVTOL aircraft models Lingxiao Q212 and J506, and a Super Intelligent Valet Parking system. This integrated approach aims to ov...
At the 2026 Chery International User Summit, Chery introduced a connected mobility ecosystem featuring a Level 4 Robotaxi, eVTOL aircraft Lingxiao models, and Super Intelligent Valet Parking (SIVP). This system aims to seamlessly integrate land and a...
Lumentum Holdings reported a strong Q1 with revenue up 136.5% year-over-year to $1.26 billion and adjusted operating margins expanding to 42.3%. The company saw a 228.8% increase in systems revenue and generated over $108 million from optical switchi...
Cocrystal Pharma has completed dosing in its Phase 1b challenge study of CDI-988, an antiviral drug targeting norovirus prevention and treatment, with no serious adverse events reported. Preliminary efficacy results are expected near the end of 2026,...
